PROSTATE CANCER
 
Sipuleucel-T significantly improves OS in African-Americans vs. Caucasians
Analyses of data collected in PROCEED, a large real-world registry, corroborate phase III study findings demonstrating that sipuleucel-T (Provenge) treatment for metastatic castrate-resistant prostate cancer has a particular benefit for improving overall survival in African-American men.
Learn more
 
Analysis further refines delivery of new therapies for mCRPC
"The last several years have been particularly exciting in the area of metastatic castrate-resistant prostate cancer," writes J. Brantley Thrasher, MD.
Read his editorial

 
 
SURVEY
 
Is DRE still a relevant tool in the management of prostate cancer?
 
MORE FROM UROLOGY TIMES
 
Antiandrogens may increase mortality risk in men with CVD
PSMA PET/CT beneficial for prostate cancer staging
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont